Sapient Capital LLC Cuts Stock Position in Pfizer Inc. $PFE

Sapient Capital LLC trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 1.9% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 506,874 shares of the biopharmaceutical company’s stock after selling 9,735 shares during the quarter. Sapient Capital LLC’s holdings in Pfizer were worth $12,287,000 as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in the company. Mirador Capital Partners LP increased its position in shares of Pfizer by 31.6% during the second quarter. Mirador Capital Partners LP now owns 48,575 shares of the biopharmaceutical company’s stock worth $1,177,000 after purchasing an additional 11,662 shares in the last quarter. Gateway Investment Advisers LLC increased its position in shares of Pfizer by 6.3% during the second quarter. Gateway Investment Advisers LLC now owns 1,122,631 shares of the biopharmaceutical company’s stock worth $27,213,000 after purchasing an additional 66,491 shares in the last quarter. Aaron Wealth Advisors LLC increased its position in shares of Pfizer by 10.8% during the second quarter. Aaron Wealth Advisors LLC now owns 19,292 shares of the biopharmaceutical company’s stock worth $468,000 after purchasing an additional 1,873 shares in the last quarter. Financiere des Professionnels Fonds d investissement inc. increased its position in shares of Pfizer by 14.4% during the second quarter. Financiere des Professionnels Fonds d investissement inc. now owns 427,190 shares of the biopharmaceutical company’s stock worth $10,355,000 after purchasing an additional 53,693 shares in the last quarter. Finally, Breakwater Capital Group increased its position in shares of Pfizer by 4.4% during the second quarter. Breakwater Capital Group now owns 79,670 shares of the biopharmaceutical company’s stock worth $1,931,000 after purchasing an additional 3,345 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

PFE has been the subject of several research reports. Citigroup boosted their price target on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Berenberg Bank dropped their price target on Pfizer from $28.00 to $25.00 and set a “hold” rating for the company in a research report on Thursday, May 29th. Bank of America boosted their price objective on Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Jefferies Financial Group boosted their price objective on Pfizer from $32.00 to $33.00 and gave the stock a “buy” rating in a research note on Wednesday, May 21st. Finally, Morgan Stanley upped their price target on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $28.12.

Pfizer Stock Down 0.4%

Shares of NYSE PFE opened at $23.88 on Wednesday. The stock has a market cap of $135.77 billion, a PE ratio of 12.70, a price-to-earnings-growth ratio of 0.85 and a beta of 0.55. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43. The business has a 50-day moving average price of $24.73 and a 200 day moving average price of $24.25.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business’s revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.2%. The ex-dividend date of this dividend was Friday, July 25th. Pfizer’s dividend payout ratio (DPR) is currently 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.